New Cellectis video showcases allogeneic CAR-T tech

The race to develop the world's best CAR-T therapy for cancer has inspired some fancy marketing efforts on behalf of some of the leaders in the field. Case in point: France's Cellectis ($CLLS), which is developing an R&D hub in Manhattan, has unveiled a cool new 2-minute video which illustrates how it plans to use TALEN gene editing tech to create allogeneic, or off-the-shelf, engineered T cell treatments. Keep in mind, though, that while Cellectis' approach has helped inspire a big IPO for the company, the company is also quick to acknowledge that it's only been tried in animals so far. The first human study lies ahead.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.